Based on earlier studies of T-cell therapy of melanoma patients were as low as 1,3 × 109 infused cells containing 30% MART-1-specific CD8+ T-cells mediated a complete clinical response [17], we estimate that a minimum of 3 × 109 cells are required to obtain a therapeutic effect. This evidence concerns the gene CD8A and melanoma.